Skip to main content

Table 2 Incident NTM infection categorized by the year after the diagnosis of SS

From: The risk of nontuberculous mycobacterial infection in patients with Sjögren’s syndrome: a nationwide, population-based cohort study

Variable Total Event (%) Total person-years Incidence Rate (/105 years) IRR (95%CI)
The entire period
 Non- SS 98,310 9 (0.01) 312,435 3 1
 SS 6554 4 (0.06) 18,365 22 7.56 (2.33–24.55)
  SS treated without immunosuppressants 5205 1 (0.02) 14,196 7 2.45 (0.31–19.30)
  SS treated with immunosuppressants 1349 3 (0.22) 4169 72 24.98 (6.76–92.27)
 Total 104,864 13 (0.01) 330,800 4  
1st year
 Non- SS 98,310 3 (0.00) 95,803 3 1
 SS 6554 3 (0.05) 5970 50 16.05 (3.24–79.51)
  SS treated without immunosuppressants 5599 1 (0.02) 5089 20 6.27 (0.65–60.33)
  SS treated with immunosuppressants 955 2 (0.21) 881 227 72.51 (12.12–433.98)
 Total 104,864 6 (0.01) 101,773 6  
  1. Immunosuppressants: methotrexate, cyclophosphamide, or azathioprine. Abbreviations: SS Sjögren’s Syndrome, CCI Charlson comorbidity index